Low-dose hormone therapy may be beneficial in postmenopausal women with myocardial ischaemia but no obstructive coronary artery disease,

2007 ◽  
Vol &NA; (1614) ◽  
pp. 8
Author(s):  
&NA;
ESC CardioMed ◽  
2018 ◽  
pp. 2646-2650
Author(s):  
Juhani Knuuti ◽  
Antti Saraste

Preoperative non-invasive testing aims to provide informed choices about the appropriateness of surgery, guide perioperative management, and assess the long-term risk of a cardiac event through identification of left ventricular dysfunction, heart valve abnormalities, and myocardial ischaemia. Preoperative non-invasive testing is not recommended routinely, but it should be considered in patients in whom initial clinical evaluation indicates increased risk for perioperative cardiac complications and who are scheduled for intermediate- or high-risk surgery. Pharmacological stress testing combined with myocardial perfusion imaging or echocardiography is more suitable than physical exercise for the detection of myocardial ischaemia in patients with limited exercise tolerance that is common in the preoperative setting. Alternatively, non-invasive coronary computed tomography angiography can identify obstructive coronary artery disease. A negative stress testing with imaging or the absence of high-risk coronary anatomy on computed tomography angiography is associated with a low incidence of perioperative cardiac events, but the positive predictive value is relatively low, that is, the risk is relatively low despite a positive result. In patients with extensive stress-induced ischaemia or extensive obstructive coronary artery disease detected by non-invasive testing, individualized perioperative management is recommended considering the potential benefit of the proposed surgical procedure, weighed against the predicted risk of adverse outcome.


2021 ◽  
Vol 5 (7) ◽  
Author(s):  
Philopatir Mikhail ◽  
James Rogers ◽  
Cecily Forsyth ◽  
Thomas J Ford

Abstract Background Coronary vasospasm is an increasingly recognized cause of myocardial infarction or myocardial ischaemia in patients without obstructive coronary artery disease. A thorough medication review may identify drugs or toxins that could trigger coronary vasospasm. This case provides mechanistic insight into the off-target effect of proteasome inhibition leading to coronary vasospasm in a patient referred with chest pain consistent with typical angina. Case summary A 72-year-old lady presented with anginal chest pain at rest with electrocardiogram evidence of myocardial ischaemia who was referred for invasive coronary angiography. This demonstrated minor coronary disease without an obstructive lesion. Vasoreactivity testing revealed diffuse coronary vasospasm of the left anterior descending artery. Carfilzomib was identified as the trigger for coronary vasospasm. Symptoms resolved without recurrence after appropriate treatment including cessation of the triggering agent. Conclusion Coronary spasm is a rare but important adverse reaction to proteasome inhibitors. This case supports the clinical utility of invasive coronary vasoreactivity testing in patients with ischaemia with no obstructive coronary artery disease.


Menopause ◽  
2019 ◽  
Vol 26 (11) ◽  
pp. 1272-1276
Author(s):  
Jun Hwan Cho ◽  
Hack-Lyoung Kim ◽  
Myung-A Kim ◽  
Sohee Oh ◽  
Mina Kim ◽  
...  

2009 ◽  
Vol 205 (1) ◽  
pp. 325-330 ◽  
Author(s):  
Stefania Lamon-Fava ◽  
David M. Herrington ◽  
David M. Reboussin ◽  
Michelle Sherman ◽  
Katalin Horvath ◽  
...  

Heart ◽  
2011 ◽  
Vol 97 (Suppl 1) ◽  
pp. A34-A34
Author(s):  
T. E. Ingram ◽  
R. A. Bleasdale ◽  
C. Templeton ◽  
C. Williams ◽  
A. Margulescu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document